Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
ART in Africa bridges health gap between those with, without HIV

The expansion of ART for HIV infection has helped reduce disparities in health-related quality of life between HIV-positive and HIV-negative individuals in Zambia and South Africa, according to findings published in The Lancet Global Health.

Published
13 October 2017
From
Healio
Unpacking Michael Weinstein's Latest PrEP Denialism

The controversial head of the AIDS Healthcare Foundation has taken his PrEP-skepticism campaign to the prestigious medical journal AIDS. The editorial is compromised by unsound logic, the cherry picking of evidence and the tendency to ignore important granular details about HIV infection and PrEP-use trends.

Published
13 October 2017
From
Poz
HIV controlled with improved CAR T therapy; human testing planned next spring

A breakthrough cancer treatment is to be tested in patients next year for its original purpose, controlling HIV infection.

Published
13 October 2017
From
The San Diego Union-Tribune
Symtuza protease inhibitor regimen maintains viral suppression for a year

People who switched from a multi-pill antiretroviral regimen to the first one-pill, once-daily regimen that includes a protease inhibitor maintained undetectable viral load for a year, according to

Published
13 October 2017
By
Liz Highleyman
Long-acting monoclonal antibody effective against multidrug-resistant HIV

Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, maintained viral suppression for a year in people with highly resistant HIV and limited

Published
12 October 2017
By
Liz Highleyman
Antibody-Based HIV Tx Proves Durable

The monoclonal antibody HIV drug ibalizumab, designed for patients who've developed severe drug resistance, had long-lasting protection in the 24-week extension phase of a phase III trial, researchers reported here.

Published
10 October 2017
From
MedPage Today
Impact of side-effects on retention in HIV care is underestimated, African study suggests

The impact of drug side-effects on retention in HIV care is probably being underestimated, according to an interview-based study of people taking antiretroviral treatment and

Published
10 October 2017
By
Keith Alcorn
HIV Regimen Switch May Contribute to Weight Gain

According to results of a study presented at IDWeek 2017, an increase in body weight is common in HIV patients who are switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to an integrase strand transfer inhibitor.

Published
09 October 2017
From
Monthly Prescribing Reference
Bictegravir-Containing Regimen Found to Be Non-Inferior to Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adult Patients with HIV

Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating the efficacy and safety of switching virologically suppressed HIV-1 infected adult patients from a multi-tablet regimen containing a boosted protease inhibitor (bPI) to a fixed-dose combination of bictegravir (50 mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF), a dual-NRTI backbone.

Published
04 October 2017
From
Gilead press release
New approach for AIDS: Lock HIV in reservoir cells, to die through apoptosis

With the successful suppression of the AIDS virus (HIV) through medication, the focus turns toward its eradication. Researchers have developed a new compound that is key to the destruction of HIV. When the compound is introduced into infected cells, viral budding is suppressed thereby confining it within the host cells. The cell then dies naturally through apoptosis. This treatment is hoped to lead to the complete recovery from AIDS in the near future.

Published
04 October 2017
From
Science Daily

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.